Michael Thorpy, MD, CHBC

Pooled Analysis From 12-Week Randomized, Controlled Studies of Solriamfetol in the Treatment of Excessive Daytime Sleepiness in Participants With Obstructive Sleep Apnea or Narcolepsy

Background: Solriamfetol (formerly JZP-110), a dopamine and norepinephrine reuptake inhibitor, has been approved in the US (SunosiTM) to improve wakefulness in adults with excessive dayti...

Colin Shapiro , PhD, FRCPC, MBBCh;

Michelle Baladi , PhD;

Dandan Chen , MD, PhD;

Helene Emsellem , MD;

Michael Thorpy , MD, CHBC;

Kris Liu , PhD;

Paula Schweitzer , MD, PhD;

Kimberly Babson , PhD;

11/22/2019

Misdiagnoses and Comorbidities Among Participants in the Nexus Narcolepsy Registry

Background: Narcolepsy diagnosis can be challenging. Presence of comorbidities and overlapping symptoms between narcolepsy and other conditions may contribute to diagnostic delay and misd...

David Pasta , MS;

Danielle Hyman , PhD;

Kathleen Villa , MS;

Jed Black , MD;

Maurice Ohayon , MD, DSc, PhD;

Michael Thorpy , MD, CHBC;

Michael Williams , PhD;

03/01/2019

Quality of Life, Functional Evaluation, and Work Productivity in Patients With Narcolepsy: Results From a Phase 3 Study of Solriamfetol (JZP-110)

INTRODUCTION: Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, significantly decreased excessive sleepiness in a randomized, double-blind, placebo-controlled study of...

Michael Thorpy , MD, CHBC;

Giuseppe Plazzi , MD;

Yves Dauvilliers , MD, PhD;

Colin Shapiro , PhD, FRCPC, MBBCh;

Jed Black , MD;

Geert Mayer , MD;

Helene Emsellem , MD;

Dandan Chen , MD, PhD;

Robert Ryan , MS;

Gert Jan Lammers , PhD, MD;

Chevy Chase , MD;

Lawrence Carter , PhD;